$MLRT - MetAlert took a significant step forward in the fourth quarter of 2022 by eliminating all toxic convertible notes from its balance sheet. This move, along with improved guidance to operations, provides investors with increased stability to the public float. In addition, MetAlert is launching new medical devices geared toward the geriatric and autism healthcare markets. With these developments, a recent report price targets MetAlert now at $1 per share.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.